Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Operating Margin
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
Z
|
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
|
12.2B CNY |
14%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
752.4B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
371.6B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
214.2B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
183.8B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
164.5B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
210.5B USD |
35%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
120.2B EUR |
22%
|
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Glance View
Founded in 1973, Zhejiang Jiuzhou Pharmaceutical Co. Ltd. has steadily navigated the evolving tides of the global pharmaceutical industry with a compelling blend of innovation and traditional business acumen. Rooted in China's dynamic Zhejiang province, the company initially focused on manufacturing basic pharmaceutical intermediates. Over the years, it strategically expanded its operations, becoming a key player in both the Active Pharmaceutical Ingredients (APIs) and Contract Development and Manufacturing Organization (CDMO) sectors. This dual focus has allowed Jiuzhou Pharmaceutical to innovate and offer comprehensive services, ranging from drug development to commercial manufacturing, effectively appealing to a broad range of customers including some of the world's leading pharmaceutical companies. At the heart of Jiuzhou Pharmaceutical's success lies its commitment to research and development, a cornerstone that supports its diversification strategy. The company leverages its extensive expertise and cutting-edge technology to improve existing drugs while also participating in the development of new, patented pharmaceuticals. By fostering strong partnerships with global pharmaceutical giants, Jiuzhou effectively integrates itself into the larger pharmaceutical ecosystem, providing customized solutions that resonate with market demand. This business model not only reinforces its financial growth but also establishes Zhejiang Jiuzhou as an indispensable contributor to advancements in medicine, continually enhancing its reputation on the international stage.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Zhejiang Jiuzhou Pharmaceutical Co Ltd's most recent financial statements, the company has Operating Margin of 13.7%.
You don't have any saved screeners yet